Opendata, web and dolomites

Hyalcis

Hyaluronic-Cisplatin Film for Implant in Malignant Mesothelioma Recurrence

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Hyalcis project word cloud

Explore the words cloud of the Hyalcis project. It provides you a very rough idea of what is the project "Hyalcis" about.

planning    asbestos    malignant    registration    43    difficult    animals    feedback    worldwide    market    epithelial    biodegradable    achievable    cisplatin    people    25    efficiency    company    plumestars    effectiveness    recurrence    industry    situ    surfaces    200m    treat    industrialization    prolonged    2016    america    toxicity    financial    hyalcis    die    innovative    concentrations    competitors    tumor    north    safety    obtaining    linked    flexible    years    opportunity    extremely    reaching    qualified    preparation    hydrophilic    local    construction    benefits    agency    prevention    precisely    capture    pleura    rare    confirmed    medical    japan    business    surgery    provider    orphan    form    disease    drug    diagnose    entitles    plan    successfully    tests    adhering    solution    limiting    districts    combined    feasibility    mesothelioma    intrapleural    treatment    polymeric    recovery    sufficiently    mesothelial    introduces    residual    thin    anticancer    australia    medicinal    proposing    satisfactory    resistant    curative    release    aggressive    months    film    full    designation    pleural    cancer    protection   

Project "Hyalcis" data sheet

The following table provides information about the project.

Coordinator
PLUMESTARS SRL 

Organization address
address: STRADA INZANI 1
city: PARMA PR
postcode: 43124
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.plumestars.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PLUMESTARS SRL IT (PARMA PR) coordinator 50˙000.00

Map

 Project objective

Hyalcis is a novel medicinal product, based on an innovative biodegradable film technology, for the prevention of the recurrence after surgery of malignant pleural mesothelioma. The proposing company, PlumeStars s.r.l., has successfully applied to the European Medical Agency, obtaining in 2016 the orphan designation for Hyalcis. This entitles PlumeStars as unique provider of the product, i.e, a polymeric film to treat pleura mesothelioma, for which there are no satisfactory curative methods. To capture this unique business opportunity, the Phase 1 project will develop a detailed Business Plan achievable within 6 months, including technical feasibility assessment based on qualified feedback and requirements from users, detailed market analysis, competitors analysis, industrialization planning, key partnerships preparation, knowledge protection and financial planning. Mesothelioma is a very aggressive form of cancer linked to asbestos use in construction and industry. It is difficult to diagnose, highly resistant to treatment and full recovery is extremely rare. Over 43,000 people die every year worldwide for the disease and that 10,000 new cases of mesothelioma combined in Europe, North America, Japan and Australia occur each year. The solution developed by PlumeStars is a hydrophilic, thin and flexible film, sufficiently resistant to be applied intrapleural or in other districts, adhering to the mesothelial or epithelial surfaces. The cisplatin release from the film is prolonged providing high local concentrations of anticancer drug, precisely in situ where the residual tumor could develop. This introduces significant benefits in terms of effectiveness, limiting tumor recurrence, low toxicity and increased safety and efficiency. This benefits have been confirmed in the tests already carried out on animals. PlumeStars aims at reaching 25% of the 200M€/year target market in 5 years, including 2 years for industrialization and registration.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HYALCIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HYALCIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TalentVision (2019)

INSIGHTS FOR TALENT ASSESSMENT USING COMPUTER VISION TECHNIQUES FROM NEURO PSYCHOLOGY

Read More  

Manuback (2019)

MANUBACK, the smart garment for operator protection in the field of Manual Handling of Goods

Read More  

Nocturne (2019)

The eye as a window to the brain, extending lifelong brain health

Read More